West Pharmaceutical Services, Inc. (NYSE: WST) announced that its board of directors has appointed Michel Lagarde as president and chief executive officer, effective August 31, 2026. Lagarde will also join the company's board of directors on that date.

Lagarde succeeds Eric M. Green, who will retire from his roles as president, CEO and board chair on August 31, 2026. The board elected Lead Independent Director Robert F. Friel to become board chair, also effective August 31, 2026.

Lagarde most recently served as executive vice president and chief operating officer at Thermo Fisher Scientific, Inc., where he had responsibility for the majority of the company's businesses. He joined Thermo Fisher in 2017 as senior vice president and president of Pharma Services through the acquisition of Patheon N.V.

Prior to Thermo Fisher, Lagarde was president and chief operating officer at Patheon N.V. from 2016 to 2017, and managing director at JLL Partners, a private equity firm focused on healthcare services, from 2008 to 2016. Earlier in his career, he spent 12 years at Philips in finance roles across international markets.

Lagarde joined the board of directors of Vertex Pharmaceuticals in 2023, where he serves as chair of the Audit and Finance Committee. He holds a Bachelor of Business Administration from European University in Antwerp, Belgium, and an executive master's degree in finance and control from Maastricht University in the Netherlands.

West Pharmaceutical Services is headquartered in Exton, Pennsylvania, and generated $3.07 billion in net sales in fiscal year 2025. The company provides injectable drug delivery solutions and services to pharmaceutical and biotech companies worldwide.